What is the most common cause of community-acquired pneumonia (CAP) in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Most Common Cause of Community-Acquired Pneumonia

Streptococcus pneumoniae (pneumococcus) is definitively the most common cause of community-acquired pneumonia in adults, accounting for approximately two-thirds of all bacteremic pneumonia cases and consistently identified as the leading bacterial pathogen across all severity levels from outpatient to ICU settings. 1, 2

Evidence Hierarchy

The most authoritative evidence comes from multiple IDSA/ATS guidelines spanning two decades, all consistently identifying pneumococcus as the predominant pathogen:

  • S. pneumoniae is identified in 20-60% of CAP cases where a pathogen is determined, making it the single most frequently isolated organism 1
  • In outpatient settings, pneumococcus accounts for 9-20% of all episodes when using sputum culture, and up to 36% when using more sensitive detection methods 1, 2
  • Among hospitalized patients, pneumococcus represents 39% of identified pathogens (95% CI: 36.1-41.8%) 1
  • In severe CAP requiring ICU admission, pneumococcus accounts for 21.6% of identified cases (95% CI: 15.9-28.3%) and represents over 80% of all bacteremia cases 1, 3

Secondary Pathogens by Frequency

After pneumococcus, the pathogen hierarchy differs by clinical setting:

Outpatient CAP:

  • Mycoplasma pneumoniae: 13-37% of cases, particularly during epidemic years 1, 2, 4
  • Respiratory viruses: up to 36% of cases, with influenza being predominant 1, 2
  • Chlamydophila pneumoniae: up to 17% of outpatients 1

Hospitalized non-ICU patients:

  • Haemophilus influenzae (nontypeable): 3-10% of cases, especially in patients with underlying bronchopulmonary disease 1, 2
  • Mycoplasma pneumoniae: 10.8% of hospitalized patients 1
  • Respiratory viruses: 12.8% of hospitalized cases 1

ICU/Severe CAP:

  • Legionella species: 17.8% of ICU admissions (significantly higher than non-ICU settings at 3.6%) 1, 2
  • Staphylococcus aureus: 8.7% of ICU cases, particularly during influenza outbreaks 1

Critical Diagnostic Caveat

No pathogen is identified in 40-70% of CAP cases despite comprehensive diagnostic testing 1, 4, 3. This does not diminish the importance of pneumococcus—studies suggest many culture-negative cases are actually undetected pneumococcal infections, as outcomes in pathogen-negative patients mirror those with confirmed pneumococcal disease 1.

Mixed Infections

Mixed infections occur in 8-40% of cases where pathogens are identified, most commonly pneumococcus co-infected with a respiratory virus 2, 3. This reinforces that pneumococcus remains the dominant bacterial threat even when viral pathogens are present 2.

Clinical Implications

The overwhelming predominance of pneumococcus across all CAP severity levels explains why empiric antibiotic regimens universally prioritize antipneumococcal coverage, with beta-lactams forming the backbone of therapy for hospitalized patients 1. The 2007 IDSA/ATS guidelines explicitly state that empiric therapy must cover pneumococcus regardless of clinical presentation, as no clinical features reliably distinguish pneumococcal from atypical pathogen infection 1, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Causes of Community-Acquired Pneumonia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Causative Organisms in Community-Acquired Pneumonia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Community-Acquired Pneumonia Etiology

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Why does community-acquired pneumonia (CAP) cause pneumothorax, especially in patients with compromised immune systems or underlying medical conditions like chronic obstructive pulmonary disease (COPD), asthma, or cystic fibrosis?
What is the definition, epidemiology, etiology, pathogenesis, clinical presentation, diagnosis, scoring systems, differential diagnosis, treatment, and complications of Community-Acquired Pneumonia (CAP), including the role of steroids in treatment?
What is the most common cause of Community-Acquired Pneumonia (CAP) in an otherwise healthy adult?
What is the most common organism causing Community-Acquired Pneumonia (CAP)?
What is the best course of treatment for a patient with very severe COPD (Chronic Obstructive Pulmonary Disease) (Gold E) experiencing an acute exacerbation secondary to unilateral community-acquired pneumonia?
What is the treatment approach for a patient with parotiditis according to the Mexican clinical practice guidelines (GPC mexicana)?
Can hydrochlorothiazide (HCTZ) cause hypercalcemia in patients, particularly those with underlying conditions affecting calcium metabolism?
What are the management guidelines for a patient on blood thinners, including warfarin (International Normalized Ratio (INR) monitoring) and direct oral anticoagulants (e.g. apixaban, rivaroxaban)?
What are the treatment options for a patient experiencing symptoms of Cholinergic Urticaria?
What is the typical number of parotiditis episodes a child can have?
How to approach a male patient over 50 with symptoms of benign prostatic hyperplasia (BPH), such as urinary hesitancy, frequency, or nocturia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.